Home
Biosimilars and Biobetters
1 October - 2 October 2013
Biosimilars and Biobetters

SAE Media Group are proud to introduce their fourth annual Biosimilars & Biobetters conference due to met on the 1 & 2 October 2013 in London. This conference aims to build on the progress made in the previous extremely successful meetings; further developing the ideas and strategies that have been made over the past twelve months.


Biological therapeutics promises to be a radical step forward for many pharmaceutical companies pipelines; patent expiry dates are playing an important role in why many pharma companies are pushing for innovative steps to be taken in this field. Following on from our huge 2012 event, we aim to bring together pharma, biotech, CROs with regulatory bodies and legal experts to explain the advantages and disadvantages of a hugely lucrative but young market.
 

FEATURED SPEAKERS

Josh Adelson

Josh Adelson

Director, Commercial Development, Business Development Biosimilars, Pfizer
Thomas Klein

Thomas Klein

European and Swiss Patent Attorney, Roche

Amanda Gibbons

Director, Voisin Consulting Life Sciences
Amanda Gibbons

Brian Lovatt

Managing Director & Chief Executive, Vision Healthcare Consultancy Ltd
Brian Lovatt

Christopher Stothers

Partner, Arnold and Porter
Christopher Stothers

Dominic Adair

Senior Associate, Bristows
Dominic Adair

Franzpeter Bracht

Chief Financial & Business Officer, Glycotope GmbH
Franzpeter Bracht

Gary Walsh

Professor Industrial Biochemistry, University Of Limerick
Gary Walsh

Isabel Zwart

Senior Consultant, Parexel International
Isabel Zwart

Jennifer Campbell

Director World Wide Biosimilars Program, Merck Millipore
Jennifer Campbell

Josh Adelson

Director, Commercial Development, Business Development Biosimilars, Pfizer
Josh Adelson

Liz Fuller

Partner, Bird & Bird
Liz Fuller

Malcolm Mitchell

Director, BioPharmaceuticals, Eli Lilly & Co
Malcolm Mitchell

Matthew Baker

CEO & CSO, Antitope
Matthew Baker

Paul Ashton

President & CEO, pSivida
Paul Ashton

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Richard Dicicco

Rodeina Challand

Executive Director, Biosimilars Development, Scientific Affairs,, PRA International
Rodeina Challand

Steinar Madsen

Medical Director, Norwegian Medicines Agency
Steinar Madsen

Thomas Klein

European and Swiss Patent Attorney, Roche
Thomas Klein

Yahia Elsadek

Consultant , Elsadek Consulting
Yahia Elsadek

Conference agenda

clock

8:30

Registration & Coffee

clock

8:50

Registration and coffee

clock

9:00

Chairman's Opening Remarks

clock

9:10

Lecture: Linking Performance to Strategy in the Pharmaceutical Emerging Markets

  • Measuring tangible or intangible assets
  • Limitations of relying only on financial measures
  • Characteristics of a good PMS
  • The emergence of the BSC
  • Linking multiple scorecard measures to a single strategy
  • Experience with BSC implementation
  • Key success  factors for the BSC implementation
  • clock

    9:15

    Welcome and Introductions

    clock

    9:25

    Biosimilars: What are they and what are the current challenges in Europe?

     

    ·         Commercial challenges of launching biosimilars in Europe
    ·         Regulatory challenges of launching a biosimilar in Europe
    ·         Case study: Successfully launched biosimilars in the UK to date
    -          What obstacles did they have to overcome?
    -          The future of Biosimilars ( Insulin, recombinant protein, monoclonal antibodies and interferons)

    clock

    10:00

    Current regulatory processes in Europe

     

    ·         Current EMEA guidelines
    ·         Recent changes to these guidelines
    ·         How this will impact regulatory approval
    ·         Case Study: Successful and unsuccessful applications

    clock

    10:30

    Morning Coffee

    clock

    10:30

    Current state of regulatory processes in the US

     

    ·         Recent changes to help assist regulatory approval times
    ·         How this differs from previous legislation
    ·         Europe vs US
    ·         The effectiveness of these changes and how this may shape the new regulatory system in Europe

    clock

    11:00

    Workshop: Case study

  • SWOT analysis
  • Objective setting
  • Segmentation, targeting and positioning strategy
  • Customer value proposition
  • Promotion mix elements
  • Annual plan of action
  • clock

    11:00

    Morning Coffee

    clock

    11:15

    Commercialising Biosimilars and Patent/ IP issues

     

    ·         The challenges of commercialisation in Europe
    ·         The reality of commercialising a biosimilar in the states

    clock

    11:40

    Group Presentation & Discussion

    clock

    12:05

    The future landscape of Biosimilars

     

    ·         The current patent issues
    ·         Current EU patent system
    ·         Current US patent system
    -          A case study: The Submarine Patent- Etanercept
     
    ·         Future EU unitary patent system: How would this work? What difference will it make?

    clock

    12:20

    Close of Workshop

    clock

    12:20

    Welcome & Introductions

    clock

    12:25

    Discussion Session

    clock

    12:30

    Overview - Biosimilars? Biogenerics? Follow-on Biologicals?

  • What are we actually talking about?
  • Summary of issues affecting Biosimilars
  • Regulatory, Legal / IP, Commercial
  • Interchangeability - what is the issue?
  • clock

    13:00

    Biosimilars - the commercial reality

  • What is the big attraction?
  • What has happened so far?
  • Patents, IP and other issues
  • Where do Biosimilars go from here?
  • clock

    13:00

    Close of Masterclass

    clock

    14:00

    Afternoon Tea

    clock

    14:45

    The Future

  • Who will be the winners - BigPharma or low cost generic manufacturers?
  • MAbs - an opportunity for Big Pharma to catch up?
  • US Biosimilar guidelines
  • Future markets
  • Two-way split – Regulated vs unregulated
  • clock

    16:00

    Close of Workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

    clock

    9:10

    A clinical pharmacologist’s view of Biosimilars

    Malcolm Mitchell

    Malcolm Mitchell, Director, BioPharmaceuticals, Eli Lilly & Co

  • PK and/or PD
  • Population to Study
  • Design of Study
  • 3-way comparison-a need too far
  • clock

    9:50

    Biosimilar guidelines in the USA: Why industry has not yet filed a 351k

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

  • Summary of the USA Law
  • FDA’s non-legal barriers for filing a 351k
  • Deficiencies of the FDA Published Guidelines
  • FDA’s Scientific Advice
  • Best strategies to avoid the pathway and still be reimbursed by payers with physician and patients’ acceptance
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Pfizer Biosimilars Update: Where are we? What does the future hold?

    Josh Adelson

    Josh Adelson, Director, Commercial Development, Business Development Biosimilars, Pfizer

    clock

    11:40

    Biosimilars: naming, substitution and interchangeability

    Rodeina Challand

    Rodeina Challand, Executive Director, Biosimilars Development, Scientific Affairs,, PRA International

  • Naming and traceability
  • Pharmacovigilance considerations
  • Current status with substitution and Interchangeability
  • Regulatory framework
  • US state Biosimilar bills
  • Study designs: can it be done?
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    How to encourage physicians and patients to use biosimilars

    Steinar Madsen

    Steinar Madsen, Medical Director, Norwegian Medicines Agency

  • Physicians and patients views on biosimilars
  • Which information is needed?
  • Who will decide?
  • clock

    14:30

    Biotech patenting and litigation

    Thomas Klein

    Thomas Klein, European and Swiss Patent Attorney, Roche

  • Patenting strategies for biotech molecules
  • Litigation strategies, in particular in emerging markets
  • Case study
  • clock

    15:10

    BioSuperiors: an alternative concept between NBEs and Biosimilars

    Franzpeter Bracht

    Franzpeter Bracht, Chief Financial & Business Officer, Glycotope GmbH

  • Difference between Biobetters and BioSuperiors: Biosuperiors have to show a significant clinical benefit
  • BioSuperiors: Better in regard to cost x risk vs. potential reward compared to NBEs as well as BioSimilars
  • Example for a BioSuperior already at the market and based on glycooptimisation: Aranesp™
  • Example from Glycotopes Pipeline: CetuGEX ™
  • clock

    15:40

    Afternoon Tea

    clock

    16:10

    Avoiding injunctions in biologics patent litigation

    Christopher Stothers

    Christopher Stothers, Partner, Arnold and Porter

    Compulsory licences?
    Ethical or public health imperatives?
    Competition law?
    Strategic litigation

    clock

    16:50

    UK patent litigation on biologics

    Dominic Adair

    Dominic Adair, Senior Associate, Bristows

  • An overview of recent cases, including MedImmune v Novartis and Lilly v HGS
  • The litigation pitfalls of broad claim drafting
  • Issues surrounding SPCs
  • Predictions for litigation involving biosimilars
  • clock

    17:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

    clock

    9:10

    Linking performance to strategy in the pharmaceutical emerging markets

    Yahia Elsadek

    Yahia Elsadek, Consultant , Elsadek Consulting

  • Measuring tangible or intangible assets
  • Limitations of relying only on financial measures
  • Characteristics of a good PMS
  • The emergence of the BSC
  • Linking multiple scorecard measures to a single strategy
  • Experience with BSC implementation
  • Key success  factors for the BSC implementation
  • clock

    9:50

    Biosimilars: an analysis of EU product approvals

    Gary Walsh

    Gary Walsh, Professor Industrial Biochemistry, University Of Limerick

  • Sourced primarily from regulatory documentation, this work analyzes in detail the regulatory data that underpinned the approval of authorized biosimilars in the EU
  • The data is contextualized in terms of biosimilar guidelines
  • The duration of regulatory consideration of biosimilar applications to those of additional biopharmaceutical applications received within the same timeframe is compared.
  • Likely further developments in EU biosimilar regulatory policy is considered
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Sustained delivery: A Simple Route to BioBetter

    Paul Ashton

    Paul Ashton, President & CEO, pSivida

  • Controlled Delivery
  • Bioerodible
  • Simple Formulation
  • clock

    11:40

    Speeding map to clinic: A predetermined mab process template for your biosimilar

    Jennifer Campbell

    Jennifer Campbell, Director World Wide Biosimilars Program, Merck Millipore

  • Predefined process parameters in a mab template
  • Minimising process design
  • Ensuring process robustness
  • Case study: Down stream process development
  • clock

    12:20

    EU Legal developments and strategies for Biosimilars

    Liz Fuller

    Liz Fuller, Partner, Bird & Bird

  • EU legislation framework and case law
  • Key questions and strategic issues
  • Looking into the future: upcoming developments, revision of the guidelines and next steps
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Market Access issues for Biosimilars

    Brian Lovatt

    Brian Lovatt, Managing Director & Chief Executive, Vision Healthcare Consultancy Ltd

  • Pricing and Reimbursement
  • Health Technology Assessment
  • Guidelines Listing
  • Prescriber Preference
  • clock

    14:40

    Follow-On Biologics : Differences (& Similarities!) between BioSimilars and BioBetters - A Regulatory Perspective.

    Amanda Gibbons

    Amanda Gibbons, Director, Voisin Consulting Life Sciences

  • Present real-case examples of biobetters currently in development
  • Discuss what differentiates biobetters from biosimilars and also highlight some similarities
  • Envisage potential developments in the definition of a regulatory framework for biobetters
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    Assessing the needs of biosimilars and biobetters from a regulatory perspective

    Isabel Zwart

    Isabel Zwart, Senior Consultant, Parexel International

  • The differences in regulatory pathways for biosimilars and biobetters
  • How similar is similar? Do minor product modifications negate the biosimilar paradigm?
  • Can reduced development programs support the approval of biobetters?
  • What options exist for biobetters, and what are the likely regulatory implications?
  • clock

    16:20

    Key factors in the generating of anti-drug antibody responses including the importance of T cell help

    Matthew Baker

    Matthew Baker, CEO & CSO, Antitope

  • Data showing the benefits of assessing drug immunogenicity by measuring induction of CD4+ T cell responses
  • Comparison of innovator and biosimilar products for the capacity to induce T cell responses in vitro
  • CMC related factors that can modulate T cell activation
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day Two


    Partner
    Arnold and Porter
    Chief Financial & Business Officer
    Glycotope GmbH
    Managing Director & Chief Executive
    Vision Healthcare Consultancy Ltd
    Director World Wide Biosimilars Program
    Merck Millipore
    Professor Industrial Biochemistry
    University Of Limerick
    CEO & CSO
    Antitope
    Director, Commercial Development, Business Development Biosimilars
    Pfizer
    Chairman
    Harvest Moon Pharmaceuticals
    Executive Director, Biosimilars Development, Scientific Affairs,
    PRA International
    Consultant
    Elsadek Consulting
    Senior Consultant
    Parexel International
    President & CEO
    pSivida
    Director
    Voisin Consulting Life Sciences
    Director, BioPharmaceuticals
    Eli Lilly & Co
    Partner
    Bird & Bird
    Senior Associate
    Bristows
    European and Swiss Patent Attorney
    Roche
    Medical Director
    Norwegian Medicines Agency

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.